Introduction: Breast cancer is the second most common cancer in premenopause age, has a better outcome now. Increasing early detection rates and the effectiveness of adjuvant chemotherapy treatments are factors that influence the prognosis dan survival rate. However, adjuvant chemotherapy treatment can lead to ovarian dysfunction resulting in decreased quality of life.
Case: A-29-year-old woman with breast cancer received a chemotherapy regimen of Docetaxel, Doxorubicin, and Cyclophosphamide for six cycles and had no menstrual bleeding (amenorrhoea) after chemotherapy finished. Physical examination, gynecology, and ultrasound showed no abnormalities. However, the Anti-Mullerian Hormone (AMH) immunoserology laboratory test showed shallow results.
Conclusion: The gonad toxicity effects of chemotherapy on breast cancer can cause premature ovarian failure, which can manifest as oligomenorrhea, amenorrhea, or known as chemotherapy-induced amenorrhea (CIA), which can lead to induction of premature menopause or chemotherapy-induced menopause (CIM).